ArticleJournal of asthma and allergy2010
A systematic review of economic evaluations of therapy in asthma.
Article in Journal of asthma and allergy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Economic evaluation of community acquired pneumonia management strategies: A systematic review of literature.PloS one · 2019Pooled it
- Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review.PharmacoEconomics · 2018Pooled it
- Potential savings from increasing adherence to inhaled corticosteroid therapy in Medicaid-enrolled children.The American journal of managed care · 2015Article
- Cost-effectiveness of initiating extrafine- or standard size-particle inhaled corticosteroid for asthma in two health-care systems: a retrospective matched cohort study.NPJ primary care respiratory medicine · 2014Article
- Omalizumab, an anti-immunoglobulin E antibody: state of the art.Drug design, development and therapy · 2014Article
- An estimate of asthma prevalence in Africa: a systematic analysis.Croatian medical journal · 2013Article
- LABA monotherapy in asthma: an avoidable problem.The British journal of general practice : the journal of the Royal College of General Practitioners · 2013Article
- Update on optimal use of omalizumab in management of asthma.Journal of asthma and allergy · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAsthma's cost-effectiveness is a major consideration in the evaluation of its treatment options. Our objective was to perform a systematic review of the cost-effectiveness of asthma medications.
methodsWe performed a systematic search of MEDLINE, EMBASE, CINAHL, Cochrane Database of Systematic Reviews, OHE-HEED, Database of Abstracts of Reviews of Effects, Cochrane Central Register of Controlled Trials, Health Technology Assessments Database, NHS Economic Evaluation Database, and Web of Science and reviewed references from key articles between 1990 and Jan 2008.
resultsA total of 49 RCTs met the inclusion criteria. Maintenance therapy with inhaled corticosteroids was found to be very cost-effective and in uncontrolled asthmatics patients currently being treated with ICS, the combination of an ICS/LABA represents a safe, cost-effective treatment. The simplified strategy using budesonide and formoterol for maintenance and reliever therapy was also found to be as cost-effective as salmeterol/fluticasone plus salbutamol. Omalizumab was found to be cost-effective. An important caveat with regard to the published literature is the relatively high proportion of economic evaluations which are funded by the manufacturers of specific drug treatments.
conclusionFuture studies should be completed independent of industry support and ensure that the comparator arms within studies should include dosages of drugs that are equivalent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.